Current state of immunotherapy for bladder cancerWassim Kassouf
Department of Urology, Unit 446, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Expert Rev Anticancer Ther 4:1037-46. 2004
....
- An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer
Wassim Kassouf
Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Urology 70:822-5. 2007
..We sought to evaluate the optimal injection scheme and feasibility of magnetic resonance imaging (MRI) using a surrogate solution to assess the distribution of injectate in an orthotopic canine model...
- Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
Guru Sonpavde
Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
BJU Int 108:687-92. 2011
..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
- Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma
Harun Fajkovic
Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10065, USA
J Urol 187:845-51. 2012
..We assessed the prognostic value of extranodal extension and other lymph node parameters in a large multicenter cohort of patients with lymph node metastasis after radical nephroureterectomy...
- Organ preservation for muscle-invasive bladder cancer by transurethral resection
Dan Leibovici
Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Urology 70:473-6. 2007
..To determine the feasibility of bladder preservation using transurethral resection for patients with muscle-invasive cancer and to determine the proportion of patients with muscle-invasive disease who would be eligible for this approach...
- Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC
Wassim Kassouf
Department of Urology and the Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 26:121-6. 2008
..To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy...
- Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
Guru Sonpavde
Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
J Urol 185:456-61. 2011
..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
- Management of urethral recurrence after orthotopic urinary diversion
Jennifer M Taylor
Department of Urology and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
BJU Int 106:56-61. 2010
..Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder...
- P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors
Wassim Kassouf
Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Eur Urol 52:769-74. 2007
..To improve our understanding of its significance in a contemporary series, we performed an outcomes analysis of this cohort of patients...
- The role of radical cystectomy in patients with clinical T4b bladder cancer
Peter C Black
Department of Urology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Urol Oncol 29:157-61. 2011
..We hypothesized that select patients might achieve durable benefit from multiagent chemotherapy and extirpative surgery...
- Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract
Vitaly Margulis
Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
J Urol 184:453-8. 2010
..We created a prognostic tool for the accurate preoperative prediction of nonorgan confined upper tract urothelial carcinoma...
- Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience
Philippe E Spiess
Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 177:1330-4; discussion 1334. 2007
..We defined the growth rate and reviewed our experience in the surgical management of growing teratoma syndrome in patients with nonseminomatous germ cell tumors...
- Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy
Thomas F Chromecki
Department of Urology, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, NY 10065, USA
World J Urol 29:473-80. 2011
..The aim of the current study was to test this hypothesis in a large multicenter external validation cohort of patients treated with radical nephroureterectomy (RNU) while controlling for patient performance status...
- Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
Eugene K Cha
Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10065, USA
Eur Urol 61:818-25. 2012
..Novel prognostic factors for patients after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) have recently been described...
- Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer
Liana Adam
Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 177:1900-6. 2007
..We determined whether the inhibition of angiogenesis might contribute to the antitumor effect...
- The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy
Thomas F Chromecki
Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10065, USA
Eur Urol 61:245-53. 2012
..The prognostic impact of multifocal upper-tract urothelial carcinoma (UTUC) is poorly understood...
- A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer
Philippe E Spiess
Department of Urology, Columbia University, New York, NY, USA
BJU Int 106:194-8. 2010
....
- Vitamins C and K3 sensitize human urothelial tumors to gemcitabine
Wassim Kassouf
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 176:1642-7. 2006
..3 mm3 daily) (p < 0.05). CONCLUSIONS: Vitamins C and K3 have significant antiproliferative and apoptotic effects when used in combination. This combination enhances the efficacy of gemcitabine against bladder cancer in vivo...
- Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer
Peter C Black
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 185:693-700. 2011
..We determined whether there is functional crosstalk between epidermal growth factor receptor and platelet-derived growth factor receptor-?, and how this regulates biological functions in bladder cancer cases...
- Review of the M.D. Anderson experience in the treatment of bladder sarcoma
Philippe E Spiess
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
Urol Oncol 25:38-45. 2007
..To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma...
- The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder
Robert S Svatek
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clin Cancer Res 16:4461-7. 2010
..Here we address the value of adjuvant chemotherapy in patients undergoing radical cystectomy for UCB in an off-protocol routine clinical setting...
- Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration
Vitaly Margulis
Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 115:1224-33. 2009
..A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated with poor prognosis were identified...
- Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine prostate model
Anil M Shetty
Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Magn Reson Imaging 26:1672-7. 2007
..To quantitatively investigate the feasibility of MRI as a tool for assessing the spatial distribution of a convectively delivered agent using a canine prostate model...
- Treatment outcomes of small cell carcinoma of the prostate: a single-center study
Philippe E Spiess
Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:1729-37. 2007
..The current study was conducted to determine the clinical characteristics and prognostic features associated with prostatic small cell carcinoma (SCC)...
- Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection
Philippe E Spiess
Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 177:131-8. 2007
..We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients...
- Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era
Wassim Kassouf
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Cancer 107:1491-5. 2006
..This might be reflective of a paradigm shift that encompasses the adoption of multimodal therapy...
- Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer
Wassim Kassouf
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
J Urol 176:787-92. 2006
..Accordingly gefitinib administration concurrently or after chemotherapy might be the sequence of choice and it should be considered for future clinical trials...
- Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells
Wassim Kassouf
Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 65:10524-35. 2005
....
- Clinical applications for targeted therapy in bladder cancer
Liana Adam
The University of Texas M.D. Anderson Cancer Center, Department of Urology, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA
Urol Clin North Am 32:239-46, vii. 2005
....
- Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience
Wassim Kassouf
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Urol 175:2058-62. 2006
..Because late recurrence is not uncommon and is potentially life threatening, lifelong followup with cystoscopy is recommended...
- Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?
Philippe E Spiess
Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Urology 67:466-71. 2006
..A benefit was noted for the immediate group in the total duration of hospitalization. The development of local or distant recurrence was a predictor of poor survival...
- Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails
Wassim Kassouf
Montreal General Hospital and McGill University, Montreal, Quebec, Canada
J Urol 169:1742-4. 2003
..CONCLUSIONS: Nilutamide can achieve a significant sustained PSA response with a favorable toxicity profile. Patients with a previous antiandrogen withdrawal response have a significantly greater chance of responding to nilutamide...
